Sernova Biotherapeutics Inc · TSX:SVA
Sernova Biotherapeutics — Merger or Acquisition (2026)
16 slides from Sernova Biotherapeutics's merger presentation, 2026
Slide 1: Sernova (SVA.TO) & Seraxis Merge to Form
Sernova (SVA.TO) & Seraxis Merge to Form; Integrating Science. Working with Passion. Developing a Functional Cure for T1D.* Non-Con Q3 2026
Slide 2: Disclaimers and Forward-Looking Statements
DISCLAIMERS AND FORWARD-LOOKING STATEMENTS MUST READ This presentation is confidential and for your information only and is not intended to be distributed to or reviewed by anyone other than you. This presentation has been prepared by Sernova and is being supplied to you on a confidential basis for
Slide 3: Merger aims to create a differentiated approach to T1D cell therapy
MERGER AIMS TO CREATE A DIFFERENTIATED APPROACH TO T1D CELL THERAPY OUR MISSION: UPCOMIMG MILESTONES Working toward a potential functional cure for Type 1 Diabetes by uniting: • Merger agreement executed 1. Stem Cell–Derived Islets • Closing in November • SR-02, allogeneic insulin producing cells (I
Slide 4: What is the problem?
WHAT IS THE PROBLEM? Pump and CGN 3 Diabetic retinopathy Brain stroke Cerebrovascular Cataracts disease Glaucoma Donor Islet Transplant Cardiovascular Periodontal disease disease Published research indicates roughly 1 in 10 people with T1D die of severe hypoglycemia¹ Diabetic Peripheral nephropathy
Slide 5: Advantages of Betanova SR-02 & SR-03 stem cells
ADVANTAGES OF BETANOVA SR-02 & SR-03 STEM CELLS A HUMAN PANCREAS-DERIVED CELL LINE FOR ISLET MANUFACTURING Potent Islet Cells • In vitro tests show high insulin secretion and glucose responsiveness Developed For Organ Transplant Compatibility • Blood type 0, Rh negative, common HLA profile Streamlin
Slide 6: Betanova SR-02
BETANOVA SR-02 THIRD PARTY ASSESSMENT OF GLUCOSE RESPONSIVENESS (Data on File) • Stimulation of SR-02 beta cells with glucose induced biphasic influx of calcium that correlated with insulin secretion • Independent testing showed glucose- linked calcium influx & insulin secretion. • Potency similar t
Slide 7: SR-02 pre-clinical cell validation
SR-02 PRE-CLINICAL CELL VALIDATION PRECLINICAL ANIMAL DATA Nonfasting blood glucose by site and dose Nonfasting immunocompromised mice Blood Glucose By Site and Dose Immunocompromised Mice Fat pad, 5,000 iEQ (n=6) Fat pad, 2,500 iEQ (n=11) Manufactured Islets 600 Low Magnification Blood glucose (mg/
Slide 8: Reducing immune suppression
REDUCING IMMUNE SUPPRESSION (Investigational) Strategy #1 (IND cleared by FDA to begin study) HLA1 • Use modern immune-suppression to minimize Rationale burden, promote maximum tolerance Beta cells • Co-stimulatory blockers or others • Strong clinical evidence (SR-02) in Co-stimulatory blockers • We
Slide 9: SR-03 immune evading cells
SR-03 IMMUNE EVADING CELLS SR-03 IS GENE-EDITED TO AVOID IMMUNE TARGETING SR-02 • Loss-of-function strategy eliminates determinants of - IgG IgM Nucleus organ rejection while maintaining long-term durability - Antibodies formed against cells NO DETECTABLE ANTIBODIES OBSERVED • Rodents with humanized
Slide 10: Manufacturing: SR-02 & SR-03 allogeneic stem cell line
MANUFACTURING: SR-02 & SR-03 ALLOGENEIC STEM CELL LINE HIGH-PURITY, HIGH-POTENCY ISLETS (Preclinical) MANUFACTURING - No sorting or selection required to achieve high purity - High-compatibility, single-donor source - Hundreds of manufacturing runs completed - Type O, Rh- with common HLA profile - D
Slide 11: Completed Phase 1/2 Cell Pouch cadaveric cell clinical trial
COMPLETED - PHASE 1 / 2 CELL POUCH CADAVERIC CELL CLINICAL TRIAL Overall Objectives ▪ Demonstrate safety & tolerability of Cell Pouch/Human PRIMARY AND SECONDARY Donor Islet transplantation ENDPOINTS MET (SEE NCT03513939) ▪ Define islet release criteria predictive of clinical outcomes ▪ Establish op
Slide 12: Betanova Cell Pouch bio-hybrid organ
BETANOVA CELL POUCH BIO-HYBRID ORGAN CELL POUCH PRE-IMPLANT BIO – HYBRID ORGAN POST REMOVAL Phase 1/2 Findings on Safety and Function (Investigational) Phase 1/ 2 clinical trial for Type 1 Diabetes complete Vascularized Tissue Environment Designed to remodel the implant site into a vascularized tiss
Slide 13: Phase 1/2 trial - insulin-producing beta cells throughout Cell Pouch after 5 years
PHASE 1/ 2 TRIAL - ABUNDANT, VASCULARIZED, INSULIN-PRODUCING BETA CELLS THROUGHOUT CELL POUCH AFTER 5-YEARS 8 CHANNEL CELL POUCH TISSUE CHAMBERS: 1 2 3 4 5 6 7 8 INS vWF ▪ Positive immunofluorescent staining for Insulin, and Von Willebrand Factor (blood vessels), Glucagon & Somatostatin ▪ Rich vascu
Slide 14: FDA position on retrievability and containment for stem cell-derived islet therapy
FDA POSITION ON RETRIEVABILITY AND CONTAINMENT FOR STEM CELL- DERIVED ISLET THERAPY • FDA guidance ; a retrieval mechanism is preferable for stem cell-derived islet therapies¹·²·⁴ • Company believes a retrievable device is more likely to be required as a safety requirement • Stem cell-derived and ge
Slide 15: Patient willingness to adopt cell-based therapies for T1D
PATIENT WILLINGNESS TO ADOPT CELL-BASED THERAPIES FOR T1D IS OVERWHELMING | 2017 Survey across North America, Europe, and Asia found 72% interested in participating in clinical trials for bio-artificial pancreas systems, (Diabetes Technology & Therapeutics, 2017). | 2019 Study found ~75% expressed i
Slide 16: Thank You
Thank You Inquiries? Contact: David Burke, V.P. Investor Relations David.Burke@Sernova.com
Sernova Biotherapeutics — Merger or Acquisition (2026) on 6ix